07-1234

Sigma-Aldrich

Anti-Notch 2 Antibody, NT

serum, from rabbit

Synonym(s):
Neurogenic locus notch homolog protein 2 precursor, Notch (Drosophila) homolog, Notch 2, Notch homolog 2 (Drosophila)
eCl@ss:
32160702
NACRES:
NA.41
Pricing and availability is not currently available.

biological source

rabbit

Quality Level

antibody form

serum

antibody product type

primary antibodies

clone

polyclonal

species reactivity

mouse, human

species reactivity (predicted by homology)

rat (14/15 immuongen sequence homology)

application(s)

ELISA: suitable
immunohistochemistry: suitable (paraffin)
western blot: suitable

isotype

IgG

NCBI accession no.

UniProt accession no.

shipped in

wet ice

Gene Information

human ... NOTCH2(4853)

General description

Notch is a family of single-pass transmembrane receptor proteins that are synthesized in the endoplasmic reticulum as an inactive form and are proteolytically cleaved on an extracellular site by a furin-like convertase (S1 cleavage) in the trans-golgi network after the recognition of the RQRR sequence before it reaches the plasma membrane as heterodimers to yield an active, ligand-accessible form. The Notch family is comprised of 4 members (1-4) whose ligands include the Delta and Jagged family of ligands. These ligands cause proteolysis of Notch to liberate the intracellular domain. Cleavage results in a C-terminal fragment N(TN) and a N-terminal fragment N(EC). Following ligand binding, it is cleaved (S2 cleavage) by TNF-alpha converting enzyme (TACE) to yield a membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). This fragment is then cleaved by presenilin-dependent gamma-secretase between gly1743 and val1744 (S3 cleavage) to release the intracellular domain (NICD) from the membrane. That domain translocates to the nucleus and initiates transcription events by binding the DNA binding protein CSL. The notch family members are involved cell differentiation and development.

Specificity

Notch 2, cleaved N terminal. This epitope is exposed only after gamma secretase cleavage and is not accessible in the uncleaved form.
Other species have not been tested.

Immunogen

Epitope: Cleaved N-terminus
Synthetic peptide from the N-terminal sequence of the cleaved N intracellular domain (NICD) human Notch 2.

Application

Research Sub Category
Transcription Factors
Research Category
Epigenetics & Nuclear Function
ELISA:
1:30,000-1:90,000 dilution from a previous lot was used in a standard sandwich ELISA assay against the peptide immunogen.
Optimal working dilutions must be determined by the end user.

Immunohistochemistry(paraffin):
Representative testing from a previous lot.
Optimal Staining of NOTCH-2 Polyclonal Antibody: Squamous Cell Carcinoma
Anti-Notch 2 Antibody, N-Terminus detects level of Notch 2 & has been published & validated for use in ELISA, WB, IH(P).

Quality

Routinely evaluated by Western Blot on NIH/3T3 lysates.

Western Blot Analysis: 1:500 dilution of this lot detected cleaved NOTCH2 on 10 μg of NIH/3T3 lysates.

Target description

~72 kDa

Linkage

Replaces: PART AB5713

Physical form

Rabbit polyclonal IgG serum in buffer containing 0.02 M Potassium phosphate buffer with 0.15 M NaCl and 0.1% sodium azide

Storage and Stability

Stable for 6 months at -20°C in undiluted aliquots from date of receipt. Avoid repeated freeze/thaw cycles.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Analysis Note

Control
NIH/3T3 Cell Lysate

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Mariya T Sweetwyne et al.
Diabetes, 64(12), 4099-4111 (2015-08-22)
Notch pathway activation in podocytes has been shown to play an important role in diabetic kidney disease (DKD) development; however, the receptors and ligands involved in the process have not been identified. Here, we report that conditional deletion of Notch1...
Notch signaling components are upregulated during both endochondral and intramembranous bone regeneration.
Dishowitz, MI; Terkhorn, SP; Bostic, SA; Hankenson, KD
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society null
Nikhlesh K Singh et al.
EBioMedicine, 2(11), 1767-1784 (2016-02-13)
Retinal neovascularization is the most common cause of moderate to severe vision loss in all age groups. Despite the use of anti-VEGFA therapies, this complication continues to cause blindness, suggesting a role for additional molecules in retinal neovascularization. Besides VEGFA...
Eriko Tanaka et al.
Nature communications, 5, 3296-3296 (2014-02-15)
Activation of Notch1 and Notch2 has been recently implicated in human glomerular diseases. Here we show that Notch2 prevents podocyte loss and nephrosis. Administration of a Notch2 agonistic monoclonal antibody ameliorates proteinuria and glomerulosclerosis in a mouse model of nephrosis...
Yiwei Wang et al.
The American journal of pathology, 186(11), 2945-2956 (2016-10-30)
Up-regulation of human prion protein (PrP) in patients with pancreatic ductal adenocarcinoma (PDAC) is associated with a poor prognosis. However, the underlying molecular mechanism of PrP-mediated tumorigenesis is not completely understood. In this study, we found that PDAC cell lines...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.